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Abstract
Embedded pragmatic clinical trials (ePCTs) present an opportunity to improve care for people
living with dementia (PLWD) and their care partners but entail a particular constellation of
ethical and regulatory challenges. These challenges begin with subject identification.
Interventions may be delivered in ways that make it difficult to identify who is a human subject
and therefore who will need ethical and regulatory protections. The need for informed consent, a
core human subjects protection, must also be considered but can be in tension with the goals of
pragmatic approach. Thus, it is essential to consider whether the ePCT can be designed so that a
waiver or alteration of informed consent is justifiable. If informed consent is needed, there is the
question of how it is obtained, as investigators must acknowledge the vulnerability of PLWD—
due in part to diminished capacity and to increased dependence on others. Further, investigators
should recognize that many sites where ePCTs are conducted will be unfamiliar with research
regulations and ethics. In this report, the Regulation and Ethics Core of the National Institute on
Aging (NIA) Imbedded Pragmatic Alzheimer’s disease (AD) and AD-related dementias
(AD/ADRD) Clinical Trials (IMPACT) Collaboratory discusses key ethical and regulatory
challenges for ePCTs in PLWD. A central message is that investigators should anticipate and
address these challenges early in the design of their ePCTs, as a means of not only ensuring
compliance but also advancing the science.

Key words: dementia, ethics, informed consent, human subjects research
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Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD) affect over 5 million
individuals in the United States, and more than 16 million informal care partners.1 People living
with dementia (PLWD) commonly experience fragmented, poor quality, and high-cost care that
often fails to address their needs and those of their care partners. Presently, there is a paucity of
evidence to support the adoption of effective interventions and services into health care systems
(HCS) that improve the care of PLWD and their care partners.

The National Institute on Aging (NIA) Imbedded Pragmatic AD/ADRD Clinical Trials
(IMPACT) Collaboratory aims to remedy this evidentiary gap by building the nation’s capacity
to conduct embedded pragmatic clinical trials (ePCTs) to benefit PLWD and their care partners
in the HCS that serve them. The Regulation and Ethics Core supports this mission through
promulgation of guidance, best practices, and training materials for the research community. In
doing this, we are building on considerable work done by others, including the National
Institutes of Health HCS Research Collaboratory, and crucially extending it to PLWD.2,3
Additionally, our Core provides consultation for IMPACT Collaboratory pilot-grant applicants
and recipients as well as with new and early-stage investigators who receive IMPACT
Collaboratory career development awards.

Central to our Core’s guidance, training, and consultation activities is the fact that ePCTs in
PLWD entail a particular constellation of ethical and regulatory challenges. These challenges
begin with subject identification. Interventions may be delivered in ways that make it difficult to
identify who is a human subject and therefore who needs ethical and regulatory protections.
Because ePCT seek to evaluate interventions in actual clinical practice, research-related
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informed consent, a core human subjects protection, can sometimes conflict with study goals. In
such cases it is essential to consider whether the ePCT qualifies for a waiver of informed
consent. If it does not and informed consent is required, investigators must then design a consent
process that acknowledges the vulnerability of PLWD—due in part to diminished capacity and to
increased dependence on others. Further, investigators should recognize that many study sites
will be unfamiliar with research regulations and ethics frameworks. By highlighting these
considerations, the Regulation and Ethics Core aims to illuminate how the features of an ePCT
interdigitate with human subjects protections.

In this report, we discuss key aforementioned ethical and regulatory challenges in ePCTs for
AD/ADRD populations. Our overarching message is that investigators should anticipate and
address them early in the design of their ePCTs. This will ensure that ePCTs for PLWD reflect
ethical reasoning and also comply with relevant regulations. Moreover, attention to regulatory
and ethical issues from the outset can advance the pragmatic nature of a study and make the
research more efficient.

Blurring the research/care distinction
A sharp conceptual distinction between research and care has been central to the development of
research ethics and regulations.4,5 Yet, ePCTs are specifically designed to produce generalizable
knowledge from contexts that are as close as possible to the conditions of usual care—that is,
they blur the research/care distinction. The well-recognized Pragmatic Explanatory Continuum
Indicator Summary (PRECIS-2) and Readiness Assessment for Pragmatic Trials (RAPT) tools
allow investigators and institutional review boards (IRBs) to grade how pragmatic research is.6,7
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Features of a trial, such as delivery of the intervention, are “very pragmatic” if they are
“identical” to or as “flexible” as clinical care. An ePCT that meets these conditions promises
evidence with substantial external validity and so notable value to a health care system.
Unfortunately, there is not yet consensus that existing research ethics frameworks and regulatory
structures—particularly with respect to subject identification and informed consent—are
sufficiently flexible to appropriately guide the design and conduct of ePCTs.8 Attention to this
difficulty has recently increased, and ethical and regulatory aspects of pragmatic trial design
continue to evolve.9,10

Subject identification
It is critical, albeit not always straightforward, to identify who is and who is not a human subject
in an ePCT. This is important so investigators extend appropriate protections to those who need
them and avoid unnecessary ethical and regulatory burdens for those who do not.11,12

Subject identification involves important regulatory considerations. The Federal Policy for the
Protection of Human Subjects (Title 45 Part 46 of the Code of Federal Regulations, known as the
“Common Rule”) defines a human subject as “a living individual about whom an investigator . . .
conducting research: (i) Obtains information or biospecimens through intervention or interaction
with the individual, and uses, studies, or analyzes the information or biospecimens; or (ii)
Obtains, uses, studies, analyzes, or generates identifiable private information or identifiable
biospecimens” (45 CFR §46.102).13 The Common Rule goes on to explain that intervention
includes both physical procedures and manipulation of the subject’s environment performed for
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research purposes, and interaction includes communication or interpersonal contact between the
investigator and subject.

Interventions tested in ePCTs with PLWD are typically programmatic or environmental in nature
and implemented at the level of the unit of care—such as an entire nursing home or entire adult
day program. Random assignment to the intervention or control arm is also typically done at the
unit of care or “cluster” level. Together, these design features may complicate the usually
straightforward process of identifying human subjects. For example, imagine that a particular
nursing home is randomized to receive a training intervention for the staff and that after the
training, the investigators use data from the medical records to measure both staff behaviors and
patient health outcomes. Who are the subjects? The patient and staff environments have been
manipulated, and the investigators are gathering information. One interpretation is that the
human subjects are not only the PLWD but also facility staff and possibly other residents who
also coincidentally receive the intervention.14,15 A closely related question, raised below, is
whether facility staff in this example are “engaged in research.”

Waivers and alterations of informed consent
Written informed consent from human subjects is generally a regulatory and ethical requirement
of research.16,17 Yet, the collection of informed consent can frustrate the pragmatic nature of a
trial. A sound argument allows that a waiver or alteration of informed consent can, under certain
conditions, be ethically acceptable,19 and the Common Rule details conditions that, if met, allow
a waiver or alteration.
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In ePCTs that involve PLWD, a waiver or alteration of consent presents an ethical dilemma.18
Individual level consent is typically obtained by research staff, or in some circumstances by
clinical providers, with both approaches potentially undermining the pragmatic nature of a trial.
If the ePCT design and consent are truly not compatible, the investigator—and ultimately the
IRB—must determine if a waiver or alteration of informed consent is permissible. Researchers
conducting ePCTs with PLWD have the added responsibility of considering PLWDs’
vulnerability when assessing permissibility, as vulnerability is generally thought to merit more
rather than fewer protections. Attention to, and understanding of, the conditions that must be
met for a waiver or alteration of informed consent from the earliest phases of trial design can
facilitate adjusting the design so that a waiver or alteration of consent is possible.

Figure 1 suggests steps to help determine the need for informed consent. The first step in
assessing the need for written informed consent is to determine which aspects of the overall
study design are research components. For example, if the intervention tested in the ePCT is
itself considered a part of routine clinical practice and is delivered by usual care providers, it is
likely not research. In contrast, the use of protected health information gathered from medical
records to ascertain trial outcomes likely is research.

The next step to consider is whether some or all of the research components just identified may
qualify for waivers or alterations of informed consent. The Common Rule lists five criteria that
research proposing to waive or alter consent must conform to: (1) the research involves no more
than minimal risk to subjects; (2) the research could not practicably be carried out without a
waiver or alteration; (3) the research could not practicably be done with de-identified private
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information; (4) subjects’ rights and welfare will not be adversely affected; and (5) whenever
appropriate, the researchers will provide subjects or their legally authorized representative with
information after participation (45 CFR §46.116). All five criteria must be met to waive or alter
consent (see Figure 1).

Minimal risk
The Common Rule tasks IRBs with reviewing and assessing risks and benefits that may result
from research (45 CFR §46.111). “Minimal risk” means that “the probability and magnitude of
harm or discomfort anticipated in the research are not greater in and of themselves than those
ordinarily encountered in daily life or during the performance of routine physical or
psychological examinations or tests” (45 CFR §46.102). There has been considerable debate
about how to apply this definition in ePCTs.20

It is unclear what the proper comparator is for making a minimal risk assessment. Whose daily
life? For PLWD the concept of “minimal risk” is particularly fraught. Should the risk
assessment account for the high morbidity of AD/ADRD and the poor quality of much existing
care? If yes, PLWD could be exposed to significant risks that, paradoxically, would not exceed
“minimal risk.” A more sensible baseline is to compare the research risks to risks encountered in
the daily lives of persons with comparable impairment who live in a safe, high-quality care
setting. This “real and ideal world standard” grounds the minimal risk standard in the lives of
PLWD with an expectation that they receive appropriate care.

Practicability
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How to determine whether research could not practicably be carried out without a waiver or
alteration of informed consent is unsettled. Waiver or alteration may be appropriate if requiring
consent would compromise the scientific validity of a trial. For instance, waiver or alteration
may be appropriate if subjects declining to participate would likely result in a less representative
study population, introduce bias, and so frustrate the pragmatic goal of a trial. Practicability
should not be determined by considerations of the cost, convenience, or speed of obtaining
informed consent.21

Respecting subjects’ rights and welfare
A concern in all human subjects research is the potential of a dignitary harm when a subject is a
mere means to an end.22 Dignitary harms ought to worry us even more when the subjects are
PLWD. They progressively surrender privacy and self-control to others. In a private setting,
such as one’s own home, the terms of this surrender are personal matters, negotiated between the
person with dementia and his care partners. This negotiation becomes more challenging in
spaces, like nursing homes or adult day programs, where the private and the public are
necessarily fused. Introducing research into spaces where the public and private are so
intimately connected may carry dignitary risks to PLWD that need careful consideration.23 For
example, PLWD who live in a nursing home have a reasonable expectation of privacy in their
bedrooms—even if their bedrooms are also sites of substantial amounts of care delivery. Thus,
there may be heightened risk of dignitary harm from waiving or altering consent if a research
intervention will change the individual’s bedroom environment.
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Engagement with PLWD and their care partners will often be essential to a determination that
subjects’ rights and welfare will not be adversely affected by a waiver or alteration of informed
consent. Patient or care partner engagement in research design (and oversight), though
potentially difficult, can provide important insights and help ensure that patients’ values and
interests are respected.24

Notification
When appropriate, researchers should provide subjects with information about their research
participation, including their results. This is an opportunity for messaging, communications, and
community engagement that builds trust in and identification with the research. This can occur
through mechanisms such as notices posted in common areas of a long term care facility or
newsletters.

Obtaining informed consent
All five of the Common Rule criteria outlined above must be met to waive or alter consent. If an
ePCT (or any portion thereof) is not eligible for a waiver or alteration, the Common Rule details
how investigators should seek informed consent from those identified as human subjects (45
CFR §46.116).

When research is conducted with PLWD, the consent process must account for subjects’ broad
spectrum of cognitive impairments. It cannot be assumed that everyone diagnosed with
dementia lacks capacity to consent to the ePCT. Capacity is a task-specific ability to appreciate
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the situation and its consequences, understand relevant information, reason about options, and
communicate a choice.25

Because it is essential that investigators seek consent from PLWD if possible, they must have a
plan for assessing prospective subjects’ capacity to consent to the ePCT.25 Assessment methods
should list out the key facts a person need to understand and use a conversation-based approach
to assess understanding. Cognitive tests like the Mini Mental Status Exam (MMSE) are useful to
predict the likelihood a person will have capacity but cannot substitute for an assessment of
understanding.26 As an aside, capacity testing—particularly in longitudinal studies where
consent is ongoing and capacity testing is iterative—may offer insights into declining cognition
that can be upsetting to PLWD. This potential harm should be factored into the risk/benefit
assessment of the trial.

PLWD who lack capacity will often have a legally authorized representative (LAR).[16] The
most common approach to obtaining consent for research when the PLWD lacks capacity is to
seek surrogate consent from the LAR. Some state and local regulations distinguish the ability of
an LAR to consent to clinical care from the ability of an LAR to consent to research participation
on behalf of the PLWD. Therefore, researchers should understand the regulations governing
surrogate consent at their study sites.

Surrogate consent does not preclude the participation of the PLWD in research-related decisionmaking. Foregoing a conversation with a PWLD seems a dignitary harm. Two important ways
to demonstrate respect for PLWD are to seek their assent and respect their dissent.27,28 Thus, the
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recommended approach to obtaining consent for research participation when the PLWD lacks
decision-making capacity combines surrogate consent with subject assent or (lack of) dissent.

Given the vulnerability of PLWD, other people and institutions often control researchers’ access
to PLWD. These “gatekeepers” could include informal caregivers as well as staff and leadership
in a long-term care setting.29 These individuals are charged with protecting their rights and
welfare. While it will often be necessary to secure their permission to conduct an ePCT, this
permission is not a substitute for subject informed consent or assent.12

Additional issues
Conflicts of Interest: In situations when investigators have a financial interest in the
intervention—for example, it has been developed with a commercial intent—their primary
interest in producing generalizable knowledge is at risk of being biased by their secondary,
financial interest.30 Such conflicts of interest may bias judgments about ePCT design and
interpretation of results. Conflict management often requires the investigator-owner to step
away and instead serve as a consultant.

Unique Institutional Settings: The Common Rule applies to all research funded by the U.S.
Department of Health and Human Services (HHS), regardless of where that research occurs.
Any institution “engaged in research”—generally, when its employees are obtaining data for
research purposes or consent of human subjects—is required to have an approved Federalwide
Assurance (FWA) committing to compliance with the requirements in the Common Rule on file
with the Office for Human Research Protections (OHRP) in HSS (45 CFR § 46.103). It is also
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important to determine which individuals within the institution are “engaged in research,” as they
must be listed as study team members and receive adequate training in human subjects research.

Often, ePCTs in PLWD are conducted in institutions such as nursing homes or adult day
programs that do not typically participate in research and therefore lack familiarity with relevant
ethics frameworks and research regulations. Investigators must be attuned to the possibility that,
depending on the study design, the institutions may be considered “engaged in research.”
Investigators should consider whether the study can be altered to avoid this; if it cannot,
investigators should be willing to assist facilities in obtaining needed FWAs, human subjects
training, and IRB oversight.

Protected Health Information: Researchers conducting ePCTs will often seek to use
administrative data such as electronic health records and insurance claims routinely collected by
study sites or other health care providers to recruit their cohorts, characterize their subjects, and
measure outcomes. These data are considered protected health information and subject to the
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. The data owners
(i.e., covered entities such as nursing homes) may be aware of HIPAA requirements surrounding
the use of the data for clinical care and billing purposes, but less familiar with the requirements
surrounding the release of the data for research purposes. Researchers must understand HIPAA
authorization requirements for identifiable health information.

Beneficiary Inducement: Medicare and Medicaid serve nearly all PLWD. The federal AntiKickback Statute prohibits inducements to beneficiaries of these federal healthcare programs,
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and many states have similar prohibitions. These prohibitions are intended to prevent
overutilization of medical services, which inappropriately increases federal and state healthcare
program costs, potentially harms beneficiaries, and improperly influences patients’ treatment
decisions. Advisory Opinions from the HHS Office of the Inspector General suggest that these
prohibitions potentially apply to a range of clinical research designs and recruitment strategies.31
If an ePCT intervention is designed in a way that offers subjects something of value in return for
participation, it may implicate these beneficiary inducement prohibitions.

Conclusion
The IMPACT Collaboratory’s Regulation and Ethics Core will work to clarify and advance
understanding of the issues discussed herein (see Table 1). As our Core gains additional insights
into the particular ethical and regulatory challenges that arise when conducting ePCTs with
PLWD—such as through our pilot-grant consultations—our list of research priorities will
continue to grow and evolve. Our findings will inform the guidelines, best practices, and
training materials we develop and disseminate. Understanding and addressing ethical and
regulatory challenges early in the design of an ePCT is not just a means of ensuring compliance
but also a means of advancing the science.
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Table 1. IMPACT Collaboratory Regulation and Ethics Core Research Agenda
Topic

Description

Challenge

Our Plan

Research/care

Existing regulatory and

ePCTs are specifically designed to blur

Develop new regulatory

distinction

ethical frameworks are

or erase the research/care distinction,

and ethical frameworks

grounded in a distinction

making existing frameworks less

that are tailored to guide

between medical research

suitable or inapplicable.

the practice of ePCTs for

and medical care.

PLWD.

Subject

Appropriate human subject

ePCTs for PLWD will often employ

Develop guidance to help

identification

protections require clear

designs that include multiple

investigators clearly

criteria for identifying who

stakeholder groups as subjects (e.g.,

identify which

are the research subjects in a

nurses or care partners may be subjects

stakeholders are research

study and how they should

in addition to the PLWD) or that

subjects and how these

be recruited.

fundamentally change the recruitment

groups should be

structure (e.g., cluster randomization).

recruited.
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Informed consent

Collecting written, informed

Decision-making capacity of PLWD

Clarify how the regulatory

consent is the primary

may be impaired; traditional informed

and ethical conditions for

mechanism of demonstrating

consent can make the study population

adopting waivers or

respect for all research

less representative, potentially

modification of informed

subjects.

frustrating the aims of ePCTs.

consent should be applied
to ePCTs with PLWD.

Conflict of

Minimizing risk and

Investigators may often have

Develop policies to help

interest

ensuring research integrity

investments in the innovative products

manage conflicts of

demands strict,

that they believe will benefit PLWD.

interest, without stifling

comprehensive conflict of

scientific incentives.

interest policies.
Regulatory

Multiple laws and complex

ePCTs for PLWD may involve care

Develop guidance,

compliance for

regulatory frameworks exist

settings (e.g., nursing homes) that are

training, and checklist

new research

to protect the rights and

not accustomed to research and lack

materials to help study

settings

sites that are new to
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welfare of research subjects

dedicated staff/experts to navigate the

research understand the

(e.g., FWA, HIPAA, AKS).

regulatory environment.

relevant regulations.
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Figure 1. Logical flowchart for satisfying ethical and regulatory criteria for waivers or alterations of
informed consent. These criteria are stipulated in the U.S. Code of Federal Regulations (45 CFR 46 §116(e)).
Abbreviations: CFR = Code of Federal Regulations, LAR = legally authorized representative. * §116(d) of 45 CFR
46 describes the requirements for “broad consent for the storage, maintenance, and secondary research use of
identifiable private information or identifiable biospecimens” as an alternative to the traditional informed consent
requirements.

